Sanofi
Clinical trials sponsored by Sanofi, explained in plain language.
-
One-Shot gene therapy aims to free PKU patients from lifelong diet
⭐️ CURE ⭐️ OngoingThis study is testing a new, one-time gene therapy injection for adults with phenylketonuria (PKU). The goal is to see if the treatment is safe and if it can lower harmful blood Phe levels enough to allow participants to stop their highly restrictive, lifelong low-protein diet. R…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: ⭐️ CURE ⭐️
Last updated Mar 30, 2026 14:29 UTC
-
Early test of Next-Gen RSV vaccine begins
⭐️ VACCINE ⭐️ OngoingThis early-stage study is testing different versions of a new RSV vaccine made with mRNA technology. It will involve 240 healthy adults aged 18-49 to check if the vaccines are safe and if they trigger a good immune response against the virus. Participants will receive one shot an…
Phase: PHASE1 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 30, 2026 14:33 UTC
-
New Super-Vaccine aims to protect babies from more Pneumonia-Causing germs
⭐️ VACCINE ⭐️ OngoingThis study is testing a new vaccine designed to protect infants and toddlers from 21 strains of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. It will compare the new vaccine's safety and ability to trigger an immune response to an alread…
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 30, 2026 14:31 UTC
-
New vaccine schedule tested to protect babies from pneumococcal disease
⭐️ VACCINE ⭐️ OngoingThis study is testing whether a new 21-valent pneumococcal vaccine is safe and helps babies build immunity when given after one or more doses of an existing 20-valent vaccine. It will involve about 580 healthy infants and toddlers, who will receive the vaccines as part of their r…
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 30, 2026 14:30 UTC
-
New COVID booster targeting latest variant enters final testing
⭐️ VACCINE ⭐️ OngoingThis study is testing the safety and immune response of a new COVID-19 vaccine designed to target the Omicron JN.1 variant. It will give a single booster dose to about 120 older adults and people with health conditions that put them at high risk for severe COVID-19. All participa…
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 30, 2026 14:29 UTC
-
New mRNA shot tested to stop future bird flu outbreak
⭐️ VACCINE ⭐️ OngoingThis study is testing a new mRNA vaccine designed to protect against a specific type of bird flu (H5) that could cause a future pandemic. Researchers want to see if the vaccine is safe and if it triggers a good immune response in healthy adults. The study will test three differen…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 24, 2026 12:01 UTC
-
New pill aims to shrink enlarged hearts in rare genetic disease
Disease control OngoingThis study is testing whether a daily oral medicine called venglustat can better control heart damage in adults with Fabry disease compared to current standard treatments. About 104 participants with an enlarged heart will take either venglustat or their usual therapy for 18 mont…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 01, 2026 21:26 UTC
-
Skin jab vs. IV drip: new hope for easier cancer treatment
Disease control OngoingThis study is testing if a skin injection works as well as the standard intravenous (IV) drip to deliver a drug for relapsed multiple myeloma. It involves over 500 adults whose cancer has returned after previous treatments. The main goal is to see if the injection method is just …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 01, 2026 21:26 UTC
-
New shot aims to tame severe eczema itch and rash
Disease control OngoingThis study is testing an investigational drug called lunsekimig, given as an injection under the skin, to see if it can help adults with moderate-to-severe atopic dermatitis (eczema). About 150 participants will receive one of three different dose levels or a placebo for 24 weeks…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New injection shows promise for reversing severe hair loss
Disease control OngoingThis study is testing whether a new injectable drug called amlitelimab can help regrow hair in adults with severe alopecia areata, an autoimmune condition causing significant hair loss. 166 participants will receive either the drug or a placebo via injection for 36 weeks, followe…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Two-in-One diabetes shot tested for safety and effectiveness
Disease control OngoingThis study is testing the safety and effectiveness of a single injection that combines two diabetes medications (insulin glargine and lixisenatide) in adults with Type 2 diabetes. It is for people whose blood sugar is still not well controlled on their current pills or other inje…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug trial aims to protect transplanted kidneys
Disease control OngoingThis study is testing an investigational drug called BIVV020 to see if it can help prevent or treat a serious complication called antibody-mediated rejection in adults who have received a kidney transplant. The trial will enroll 48 participants who are either about to receive a t…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Eczema drug gets Long-Term safety check in major study
Disease control ENROLLING_BY_INVITATIONThis study is for people who have already been in a previous trial for an investigational eczema drug called amlitelimab. Its main goal is to check the long-term safety and see how well the drug continues to work for moderate to severe atopic dermatitis. About 1,663 participants …
Phase: PHASE2, PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for chronic swallowing disorder: drug trial tests Long-Term relief
Disease control OngoingThis study is testing whether the medication dupilumab can improve how the esophagus works and help it heal in adults with eosinophilic esophagitis (EoE), a chronic condition that makes swallowing difficult. About 69 participants will receive either dupilumab or a placebo for 24 …
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New injection tested for stubborn sinus problems
Disease control OngoingThis study is testing an investigational drug called itepekimab to see if it can reduce sinus inflammation and improve symptoms in adults with chronic sinusitis who don't have nasal polyps. About 60 participants will receive either itepekimab or a placebo injection for 24 weeks w…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New pill tested to tame debilitating bowel disease
Disease control OngoingThis study is testing a new oral drug called SAR443122 to see if it can help control ulcerative colitis in adults whose current treatments aren't working well enough. About 187 participants will receive either the new drug at one of three doses or a placebo for up to a year. The …
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug aims to save insulin cells in type 1 diabetes
Disease control OngoingThis study is testing whether an experimental drug called brivekimig can help protect the body's remaining insulin-producing cells in people recently diagnosed with type 1 diabetes. The goal is to see if the drug can slow the disease's progression and reduce the amount of insulin…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New shot aims to heal the gut in Tough-to-Treat celiac disease
Disease control OngoingThis study is testing an injectable drug called amlitelimab for adults with celiac disease who still have symptoms and intestinal damage despite following a strict gluten-free diet. The main goal is to see if the drug can help heal the gut lining and reduce symptoms better than a…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Major trial tests new drug combo to control dangerous transplant complication
Disease control OngoingThis study is testing whether adding the drug belumosudil to standard steroid treatment works better than steroids alone for people newly diagnosed with moderate or severe chronic graft-versus-host disease (cGVHD). cGVHD is a serious complication that can occur after a stem cell …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New injection could drastically cut bleeding episodes for hemophilia patients
Disease control OngoingThis study is testing if a new drug called fitusiran, given as an injection, can better prevent bleeding episodes in males aged 12 and older who have severe hemophilia A or B. Participants will first be monitored on their current standard treatment, then switch to fitusiran for a…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Japanese ITP patients offered continued access to promising drug
Disease control OngoingThis study allows adults in Japan with chronic immune thrombocytopenia (ITP) to continue taking the oral drug rilzabrutinib after completing a previous long-term trial. It is for participants who showed good results and acceptable safety in the earlier study and whose doctors bel…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New injection method tested for Hard-to-Treat blood cancer
Disease control OngoingThis study is testing whether giving a cancer drug called isatuximab as a simple injection under the skin works as well as the standard method when combined with other medications for multiple myeloma. It involves 118 adults whose cancer has returned or stopped responding after 1…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Tracking a new eczema treatment for kids: does it work in everyday life?
Disease control OngoingThis study aims to understand how well the medication dupilumab works for children with severe eczema in real-world settings. It will follow 143 children in Spain, aged 6 months to 11 years, for two years to see how the treatment affects their skin, itch, and quality of life. The…
Sponsor: Sanofi • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug trial targets Hard-to-Treat gut inflammation
Disease control OngoingThis study is testing whether an existing drug called dupilumab can help control symptoms in adults with moderate-to-severe ulcerative colitis who have a specific immune pattern. About 68 participants will receive either the drug or a placebo for 52 weeks to see if it reduces gut…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
15-Year gene therapy Follow-Up for rare Deaf-Blindness condition
Disease control OngoingThis study follows 9 patients for up to 15 years to monitor the long-term safety of an experimental gene therapy called SAR421869 for Usher syndrome type 1B. All participants previously received the gene therapy injection in one eye during an earlier trial. Researchers will track…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
5-Year watch: can new hemophilia drug save Patients' joints?
Disease control OngoingThis study aims to see how well a new treatment, efanesoctocog alfa, works over five years to protect the joints of people with Hemophilia A. It will follow 200 patients in the US and Japan who are already receiving this treatment as part of their standard care. The main goal is …
Sponsor: Sanofi • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Three-Year asthma injection trial seeks to reduce severe attacks
Disease control OngoingThis study is testing the long-term safety and effectiveness of an injectable drug called amlitelimab for adults with moderate-to-severe asthma. It follows 335 people who were already in a previous amlitelimab study, tracking them for up to 3 years to see if the drug continues to…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Four-Year quest for safer nerve disease control
Disease control ENROLLING_BY_INVITATIONThis study aims to understand the long-term safety and effectiveness of the drug riliprubart for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder. About 300 participants who have already been taking riliprubart in earlier studies can continue…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Pill vs. infusion: new hope for rare neurological disease
Disease control OngoingThis study is testing if a daily oral pill called venglustat can work as well as the current standard of care—biweekly intravenous infusions—for maintaining stability in people with Gaucher disease type 3. It involves about 43 adults and teenagers (12+) who are already stable on …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Tracking asthma patients on new biologic treatment for 3 years
Disease control OngoingThis study follows asthma patients who are starting treatment with Dupixent in real-world medical settings. Researchers will track 376 patients for up to 3 years to understand how well the medication works, what side effects occur, and how patients use the treatment alongside oth…
Sponsor: Sanofi • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Year-long study probes safety of nasal polyp drug for chronic sinus sufferers
Disease control ENROLLING_BY_INVITATIONThis study aims to check the long-term safety of a drug called itepekimab for adults with chronic sinusitis and nasal polyps. It is for people who have already finished a previous 52-week study with this drug. The main goal is to see if the treatment remains safe and tolerable ov…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Drug tested in youngest ever type 1 diabetes patients
Disease control OngoingThis study is testing the safety and how the body processes teplizumab in very young children (under 8 years old) who have early signs of type 1 diabetes but haven't developed full symptoms yet. About 20 children will receive the drug through daily IV infusions for 14 days, and r…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 18, 2026 14:42 UTC
-
New shot tested to shrink stubborn nasal polyps
Disease control OngoingThis study is testing whether a new injectable drug called lunsekimig can safely reduce nasal polyps and improve symptoms in adults with chronic sinusitis. Participants will receive either the drug or a placebo for 24 weeks to see which is more effective. The goal is to find a be…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 17, 2026 13:07 UTC
-
Major drug trial extends to monitor Long-Term safety for thousands with MS
Disease control OngoingThis study follows up on previous trials to check the long-term safety and side effects of the drug tolebrutinib in adults with multiple sclerosis (MS). It will include about 2,500 people who were in earlier studies for relapsing or progressive forms of MS. The main goal is to mo…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC
-
New antibody drug aims to tame MS Flare-Ups
Disease control OngoingThis study tested whether an investigational antibody drug called SAR441344 can reduce new areas of inflammation (lesions) in the brain for people with relapsing forms of multiple sclerosis (MS). About 129 participants received either the drug or a placebo to compare effectivenes…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC
-
Can a new shot keep severe eczema at bay for a full year?
Disease control OngoingThis study aims to see if a drug called amlitelimab can help people with moderate-to-severe eczema (atopic dermatitis) maintain clear skin over a full year. It includes over 1,500 participants aged 12 and older who previously responded well to the drug in earlier studies. The mai…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
Race to stop myeloma before it starts: major trial tests early drug combo
Prevention OngoingThis study is testing whether adding a new drug called isatuximab to a standard two-drug combination can delay or prevent high-risk smoldering multiple myeloma from progressing to active, symptomatic disease. It will involve about 337 patients who have the high-risk early form of…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Prevention
Last updated Apr 01, 2026 21:26 UTC
-
Massive study checks if pregnancy vaccine harms moms or babies
Prevention OngoingThis study aims to check if a common whooping cough vaccine is safe for pregnant people and their babies. Researchers will compare health records from about 365,000 people who got the vaccine during late pregnancy to those who did not get it. They will look for any differences in…
Sponsor: Sanofi • Aim: Prevention
Last updated Mar 30, 2026 14:35 UTC
-
New shot aims to stop uncontrollable skin itch
Symptom relief OngoingThis study is testing if an injectable medication called dupilumab can reduce severe, persistent itch in adults with Lichen Simplex Chronicus (LSC), a skin condition causing thick, itchy patches. About 142 participants will receive either dupilumab or a placebo injection for 24 w…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Mar 31, 2026 12:12 UTC
-
New injection tested to stop debilitating skin itch
Symptom relief OngoingThis study is testing if dupilumab, given as an injection under the skin, can reduce severe, long-term itching and improve skin appearance in adults with lichen simplex chronicus (LSC). About 138 participants will receive either the study drug or a placebo injection for 24 weeks …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Mar 30, 2026 14:33 UTC
-
New drug trial targets debilitating pain of rare genetic disease
Symptom relief OngoingThis study is testing whether an investigational drug called venglustat can reduce nerve pain and abdominal pain in people with Fabry disease. It will involve about 122 participants aged 16 and older who are not currently on treatment. For 12 months, some will receive the drug an…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Mar 30, 2026 14:32 UTC
-
Scientists test new eczema Drug's hidden effects on common pills
Knowledge-focused OngoingThis study aims to understand how a new investigational drug for eczema, called amlitelimab, might change how the body processes other common medications. It involves about 23 adults with moderate-to-severe atopic dermatitis. Researchers will measure drug levels in the blood to s…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Drug delivery test: does the device matter?
Knowledge-focused OngoingThis study aims to see if two different injection devices deliver the same amount of an investigational drug, amlitelimab, into the body. It will involve 212 healthy adult volunteers who will receive a single injection. Researchers will measure drug levels in the blood, check for…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Survey checks if doctors heed drug warnings
Knowledge-focused OngoingThis study is a survey to check if doctors and pharmacists in Saudi Arabia are aware of and following important safety warnings for the epilepsy drug Depakine (sodium valproate). It involves 3,500 healthcare professionals who prescribe or dispense the medication. No treatments ar…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
Tracking a new treatment for debilitating nasal polyps
Knowledge-focused OngoingThis study aims to gather real-world information on how adults in France with severe chronic sinusitis and nasal polyps are treated with the medication dupilumab (Dupixent). Researchers will follow 150 patients for two years to describe their health, prior treatments, and how the…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:16 UTC
-
Tracking a skin Treatment's Real-World impact
Knowledge-focused OngoingThis study aims to understand how well the medication dupilumab works for adults with prurigo nodularis, a severe itchy skin condition, in everyday medical practice. It will follow 100 patients for up to 18 months to see how their symptoms, like itch and pain, change and how the …
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:15 UTC